カテゴリ： GlobalData, アメリカ, 企業調査

Amicus Therapeutics Inc (FOLD)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Amicus Therapeutics Inc (FOLD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C10025
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：84
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Amicus Therapeutics Inc (Amicus Therapeutics) is a biotechnology company that focuses on the research, development and commercialization of small molecules drugs and orally administered drugs known as pharmacological chaperones for the treatment of rare and orphan diseases. The company’s lead product, Migalastat HCl, a small molecule is used for the treatment of Fabry disease. The other development products in the pipeline include ATB200/AT2221 for the treatment of Pompe disease, Fabry disease, and other lysosomal storage disorders; Migalastat for other conditions; and enzyme replacement therapies for other rare diseases. It has presence in the US, the UK, Ireland, France, the Netherlands, Germany, Spain, Italy and Japan. Amicus Therapeutics is headquartered in Cranbury, New Jersey, the US.

Amicus Therapeutics Inc (FOLD) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Amicus Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Amicus Therapeutics Raises USD4.7 Million in Venture Financing 12
Scioderm Raises USD20 Million in Series B Venture Financing 13
Callidus Biopharma Raises US$4.6 Million In Series A Financing 14
Scioderm Raises US$16 Million In Series A Financing 15
Scioderm Raises USD1 Million in Venture Financing 16
Partnerships 17
Amicus Therapeutics Enters into Research and Development Agreement with Perelman School of Medicine at the University of Pennsylvania 17
Amicus Therapeutics Enters Into Co-Development Agreement With Biogen Idec 18
Licensing Agreements 19
Scioderm Plans To License Pharmaceuticals To Develop Topical Products 19
Equity Offering 20
Amicus Therapeutics Raises USD300 Million in Public Offering of Shares 20
Amicus Therapeutics Raises USD258.8 Million in Public Offering of Shares 22
Amicus Therapeutics Raises USD258.8 Million in Public Offering of Shares 24
Amicus Therapeutics Raises USD103.5 Million in Public Offering of Shares 26
Amicus Therapeutics Raises USD 40 Million in Public Offering 28
Amicus Therapeutics Completes Private Placement Of Securities For US$15 Million 29
Amicus Therapeutics Files Registration Statement For Public Offering Of Securities For US$145 Million 30
Amicus Therapeutics Raises USD18.6 Million in Private Placement of Shares 31
Amicus Therapeutics Completes Public Offering Of Common Stock For US$65 Million 32
Debt Offering 34
Amicus Therapeutics Raises USD250 Million in Private Placement of 3% Notes Due 2023 34
Amicus Therapeutics Announces Public Offering Of Debt Securities For US$25 Million 36
Acquisition 37
Amicus Therapeutics Acquires Celenex 37
Amicus Therapeutics Acquires MiaMed 38
Amicus Therapeutics Acquires Scioderm 39
Amicus Therapeutics Acquires Callidus Biopharma, Drug Discovery Company, For USD130 Million 41
Amicus Therapeutics Inc – Key Competitors 42
Amicus Therapeutics Inc – Key Employees 43
Amicus Therapeutics Inc – Locations And Subsidiaries 44
Head Office 44
Other Locations & Subsidiaries 44
Recent Developments 46
Strategy And Business Planning 46
Sep 24, 2018: Amicus Therapeutics to buy Celenex for $100m upfront 46
Financial Announcements 47
Nov 05, 2018: Amicus Therapeutics announces third quarter 2018 financial results and corporate updates 47
Aug 07, 2018: Amicus Therapeutics announces second quarter 2018 financial results and corporate updates 49
May 08, 2018: Amicus Therapeutics Announces First Quarter 2018 Financial Results and Corporate Updates 51
Feb 28, 2018: Amicus Therapeutics Announces Full-Year 2017 Financial Results and 2018 Corporate Updates 53
Nov 08, 2017: Amicus Therapeutics Announces Third Quarter 2017 Financial Results and Corporate Updates 55
Aug 07, 2017: Amicus Therapeutics Announces Second Quarter 2017 Financial Results and Corporate Updates 58
May 09, 2017: Amicus Therapeutics Announces First Quarter 2017 Financial Results and Corporate Updates 60
Mar 01, 2017: Amicus Therapeutics Announces Full-Year 2016 Financial Results and Corporate Updates 62
Jan 09, 2017: Amicus Therapeutics Provides Full-Year 2017 Strategic Outlook and Financial Guidance 64
Corporate Communications 66
Sep 11, 2018: Amicus Therapeutics appoints Lynn D. Bleil as Board Director 66
Jun 08, 2018: Amicus Therapeutics Appoints President and COO Bradley L. Campbell to Board of Directors 67
Product News 68
10/04/2017: Amicus Therapeutics Announces Additional Positive Data in Pompe Disease Phase 1/2 Study at World Muscle Society 68
09/10/2018: Amicus Therapeutics announces regulatory and clinical updates for AT-GAA in Pompe Disease 70
05/15/2017: Amicus Therapeutics Announces Positive Functional Data from Initial Patients in Pompe Phase 1/2 Study 71
02/07/2018: Amicus Therapeutics Announces Additional Positive Data in Pompe Disease Phase 1/2 Study at 14th Annual WORLDSymposium 73
01/22/2018: Amicus Therapeutics Announces Presentations and Posters at 14th Annual WORLDSymposium 2018 75
Product Approvals 77
Jun 26, 2018: Amicus Therapeutics Announces European Regulatory and Clinical Updates for AT-GAA in Pompe Disease 77
Sep 21, 2017: U.S. FDA Grants Orphan Drug Designation for ATB200/AT2221 for Pompe Disease 79
Clinical Trials 80
Feb 15, 2017: Amicus Therapeutics Presents Important New Scientific Findings and Preclinical Data for Pompe Program at WORLDSymposium 2017 80
Other Significant Developments 81
Feb 27, 2018: Amicus Therapeutics Launches Healing Beyond Disease Initiatives to Change People’s Lives Living with Rare Diseases 81
Jan 08, 2018: Amicus Therapeutics Provides Full-Year 2018 Strategic Outlook and Financial Guidance 82
Appendix 84
Methodology 84
About GlobalData 84
Contact Us 84
Disclaimer 84

List of Tables
Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Amicus Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Amicus Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Amicus Therapeutics Raises USD4.7 Million in Venture Financing 12
Scioderm Raises USD20 Million in Series B Venture Financing 13
Callidus Biopharma Raises US$4.6 Million In Series A Financing 14
Scioderm Raises US$16 Million In Series A Financing 15
Scioderm Raises USD1 Million in Venture Financing 16
Amicus Therapeutics Enters into Research and Development Agreement with Perelman School of Medicine at the University of Pennsylvania 17
Amicus Therapeutics Enters Into Co-Development Agreement With Biogen Idec 18
Scioderm Plans To License Pharmaceuticals To Develop Topical Products 19
Amicus Therapeutics Raises USD300 Million in Public Offering of Shares 20
Amicus Therapeutics Raises USD258.8 Million in Public Offering of Shares 22
Amicus Therapeutics Raises USD258.8 Million in Public Offering of Shares 24
Amicus Therapeutics Raises USD103.5 Million in Public Offering of Shares 26
Amicus Therapeutics Raises USD 40 Million in Public Offering 28
Amicus Therapeutics Completes Private Placement Of Securities For US$15 Million 29
Amicus Therapeutics Files Registration Statement For Public Offering Of Securities For US$145 Million 30
Amicus Therapeutics Raises USD18.6 Million in Private Placement of Shares 31
Amicus Therapeutics Completes Public Offering Of Common Stock For US$65 Million 32
Amicus Therapeutics Raises USD250 Million in Private Placement of 3% Notes Due 2023 34
Amicus Therapeutics Announces Public Offering Of Debt Securities For US$25 Million 36
Amicus Therapeutics Acquires Celenex 37
Amicus Therapeutics Acquires MiaMed 38
Amicus Therapeutics Acquires Scioderm 39
Amicus Therapeutics Acquires Callidus Biopharma, Drug Discovery Company, For USD130 Million 41
Amicus Therapeutics Inc, Key Competitors 42
Amicus Therapeutics Inc, Key Employees 43
Amicus Therapeutics Inc, Other Locations 44
Amicus Therapeutics Inc, Subsidiaries 44

List of Figures
Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Amicus Therapeutics Inc (FOLD)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • MedImmune LLC-製薬・医療分野：企業M&A・提携分析
    Summary MedImmune LLC (MedImmune), a subsidiary of AstraZeneca Plc, is a biotechnology company. It focuses on the research, development, manufacture and marketing of small molecules and biologics to address some of the major medical needs. The company develops therapeutic proteins, monoclonal antibo …
  • Power Machines：企業の戦略的SWOT分析
    Power Machines - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Sareum Holdings Plc (SAR)：製薬・医療：M&Aディール及び事業提携情報
    Summary Sareum Holdings Plc (Sareum) is a drug discovery and development company that produces targeted small molecule therapeutics for treating cancer and autoimmune diseases. The drug research programs of the company are based on its proprietary drug discovery technology, Sareum Kinase Inhibitor L …
  • PSA International Pte Ltd：企業の戦略的SWOT分析
    PSA International Pte Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Constellium NV：企業の戦略・SWOT・財務情報
    Constellium NV - Strategy, SWOT and Corporate Finance Report Summary Constellium NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • The Cooper Companies Inc (COO)：企業の財務・戦略的SWOT分析
    The Cooper Companies Inc (COO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Abdullah Al-Othaim Markets Co.：企業の戦略・SWOT・財務分析
    Abdullah Al-Othaim Markets Co. - Strategy, SWOT and Corporate Finance Report Summary Abdullah Al-Othaim Markets Co. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Swietelsky Baugesellschaft mbH：企業の戦略的SWOT分析
    Swietelsky Baugesellschaft mbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Konsortium Transnasional Berhad：企業の戦略・SWOT・財務情報
    Konsortium Transnasional Berhad - Strategy, SWOT and Corporate Finance Report Summary Konsortium Transnasional Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Ampac Packaging, LLC：企業の戦略・SWOT・財務情報
    Ampac Packaging, LLC - Strategy, SWOT and Corporate Finance Report Summary Ampac Packaging, LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • SJVN Ltd (SJVN)-エネルギー分野：企業M&A・提携分析
    Summary SJVN Limited (SJVN), formerly Satluj Jal Vidyut Nigam Limited-SJVNL, generates and sells hydroelectric power in India. It was formed as a joint venture between the Government of India (GOI) and the Government of Himachal Pradesh (GOHP). The company also focuses on the designing, planning, de …
  • Cyxone AB-製薬・医療分野：企業M&A・提携分析
    Summary Cyxone AB (Cyxone) is a biopharmaceutical company that develops cyclotide drugs for immune-related diseases. The company’s lead product include T20K, a compound to inhibit pro-inflammatory cytokines, such as IL2 that helps to reduce clinical symptoms in an animal model for multiple sclerosis …
  • JAKKS Pacific Inc (JAKK)：企業の財務・戦略的SWOT分析
    Summary JAKKS Pacific Inc (JAKKS) is a consumer goods provider that designs, develops, produces and markets toys, leisure products and writing instruments for children and adults. The company’s products comprise dolls, role play and dress-up, halloween costumes, foot to floor ride-on vehicles, seaso …
  • SHI International Corp.：企業の戦略的SWOT分析
    SHI International Corp. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Vocalink Limited
    Vocalink Limited - Strategy, SWOT and Corporate Finance Report Summary Vocalink Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Dynegy Inc.：戦略・SWOT・企業財務分析
    Dynegy Inc. - Strategy, SWOT and Corporate Finance Report Summary Dynegy Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Optiscan Imaging Limited (OIL)-医療機器分野：企業M&A・提携分析
    Summary Optiscan Imaging Limited (Optiscan) is a technology and product development company. It focuses on the development and application of microscopic imaging technologies for medical procedures. The company’s key product is ViewnVivo, a miniaturized fluorescence endo-microscope platform that bri …
  • T-System Inc-医療機器分野：企業M&A・提携分析
    Summary T-System Inc (T-System) is a healthcare service provider that offers clinical, financial, operational, and regulatory solutions. The company offers documentation solutions, which include EV, an emergency department information system; EV for physicians, a solution with ER-specific clinical c …
  • MGB Biopharma Ltd-製薬・医療分野：企業M&A・提携分析
    Summary MGB Biopharma Ltd (MGB) is a clinical stage biopharmaceutical company which develops anti-infective medicine of minor groove binder (MGBs) compounds. The company focuses on the development of new class of small molecules, with specific antibacterial activity against susceptible and resistant …
  • Innergex Renewable Energy Inc：発電所・企業SWOT分析
    Innergex Renewable Energy Inc - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆